Transforming Vision, Transforming Lives
Beacon Therapeutics is a leading clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company uses adeno-associated virus (AAV) gene therapy to develop treatments for inherited retinal diseases including X-Linked Retinitis Pigmentosa (XLRP), dry Age-related Macular Degeneration (dAMD), and Cone Rod Dystrophy (CRD). Spun out of Syncona and the University of Oxford in 2023, Beacon raised $120M at launch and an additional $170M Series B to advance its lead candidate laru-zova through late-stage clinical trials. The company operates out of London, UK with facilities in Boston, Massachusetts and Alachua, Florida.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2023
Create a free account to see which investors have funded this company.
Create Free AccountClinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
Biopharmaceutical company developing multispecific antibody therapies for retinal and complex dis...
UK biotech developing cell conversion technology for life-saving cell therapies.
